Mark A Weiss MD

Clinical Trials

• Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Start of enrollment: 1994 Jun 01

  Completed

  Phase 2

• Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers Start of enrollment: 1998 Sep 01

  Completed

  Phase 2

• Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia Start of enrollment: 1998 Sep 01

  Completed

  Phase 2

• Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2002 Oct 01

  Completed

  Phase 1

• Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias Start of enrollment: 2006 Jan 01

  Completed

  Phase 1, Phase 2

• Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma Start of enrollment: 2009 Feb 05

  Completed

  Phase 2

• A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies Start of enrollment: 2008 Apr 10

  Completed

  Phase 2

• A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors Start of enrollment: 2011 Feb 10

  Completed

  Phase 2

• Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma Start of enrollment: 2011 May 25

  Terminated

  Phase 1

• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Start of enrollment: 2011 Aug 04

  Completed

  Phase 2

• Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide Start of enrollment: 2011 Nov 09

  Completed

  Phase 1, Phase 2

• Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant Start of enrollment: 2012 Aug 01

  Withdrawn

  Not Applicable

• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Start of enrollment: 2012 Dec 24

  Completed

  Phase 2

• Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2013 Mar 15

  Completed

  Early Phase 1

• Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Start of enrollment: 2013 Jul 08

  Active, not recruiting

  Phase 2

• Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies Start of enrollment: 2013 May 17

  Terminated

  Phase 2

• Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Jan 15

  ACTIVE_NOT_RECRUITING

  PHASE3

• Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor Start of enrollment: 2013 Nov 04

  Completed

  Phase 2

• Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2014 Aug 25

  Completed

  Phase 2

• Join now to see all